UY37644A - Polipéptidos quiméricos y métodos para alterar su localización en la membrana - Google Patents

Polipéptidos quiméricos y métodos para alterar su localización en la membrana

Info

Publication number
UY37644A
UY37644A UY0001037644A UY37644A UY37644A UY 37644 A UY37644 A UY 37644A UY 0001037644 A UY0001037644 A UY 0001037644A UY 37644 A UY37644 A UY 37644A UY 37644 A UY37644 A UY 37644A
Authority
UY
Uruguay
Prior art keywords
ligand
polypeptide
membrane
methods
domain
Prior art date
Application number
UY0001037644A
Other languages
English (en)
Inventor
Stephen Santoro
Scott Coyle
Levi Rupp
Peter Emtage
Original Assignee
Cell Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Design Labs Inc filed Critical Cell Design Labs Inc
Publication of UY37644A publication Critical patent/UY37644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Métodos, composiciones para localizar reversiblemente proteínas en exterior de superficie celular incluyendo: ácidos nucleicos que codifican polipéptidos, dominio de unión al ligando (LBD) de receptor hormonal nuclear. Adicionando el ligando, el polipéptido puede localizarse en lado extracelular de membrana plasmática; extrayendo el ligando se puede retirar polipéptido. Construcción de ácido nucleico con LBD puede incorporarse en polipéptido con dominio de unión al antígeno. Polipéptido puede introducirse en célula de mamífero; introduciendo el ligando, dicho dominio se localiza en lado extracelular de membrana; extrayendo el ligando, el dominio se retira. Aplicaciones para controlar toxicidad de linfocitos T de CAR.
UY0001037644A 2017-03-28 2018-04-02 Polipéptidos quiméricos y métodos para alterar su localización en la membrana UY37644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477733P 2017-03-28 2017-03-28
US201762587262P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
UY37644A true UY37644A (es) 2018-10-31

Family

ID=62090037

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037644A UY37644A (es) 2017-03-28 2018-04-02 Polipéptidos quiméricos y métodos para alterar su localización en la membrana

Country Status (14)

Country Link
US (2) US11111310B2 (es)
EP (1) EP3601330A1 (es)
JP (3) JP2020512009A (es)
KR (4) KR102659440B1 (es)
CN (1) CN110678480A (es)
AU (3) AU2018244592C1 (es)
BR (1) BR102018006205A2 (es)
CA (1) CA3058262A1 (es)
IL (1) IL269433A (es)
JO (1) JOP20180027A1 (es)
SG (2) SG10201912408WA (es)
TW (2) TWI811212B (es)
UY (1) UY37644A (es)
WO (1) WO2018183551A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019133199A (ru) * 2017-03-27 2021-04-28 Ф. Хоффманн-Ля Рош Аг Улучшенные форматы антигенсвязывающего рецептора
US11485789B2 (en) * 2017-11-12 2022-11-01 Jay H. Choi Modular, controlled single chain variable fragment antibody switch
US20240122980A1 (en) * 2019-10-18 2024-04-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of tim-3 cytoplasmic tail in chimeric antigen receptors
CN111995689B (zh) * 2020-08-27 2023-05-05 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
CN114149510B (zh) * 2021-10-29 2024-01-30 上海鑫湾生物科技有限公司 一种条件控制的可剪接嵌合抗原受体分子及其应用
KR20240112623A (ko) 2023-01-12 2024-07-19 엘지디스플레이 주식회사 표시 장치

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JP3700791B2 (ja) * 1994-05-26 2005-09-28 小野薬品工業株式会社 Ｆａｓ抗原融合蛋白、その蛋白をコードするＤＮＡ、そのＤＮＡを含むベクター、そのベクターで形質転換された宿主細胞、そのベクターを有効成分とする治療剤、およびその宿主細胞を用いるスクリーニング方法
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
CA2250975A1 (en) * 1996-04-15 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain g-protein-coupled receptor compositions and methods
JP2002153287A (ja) * 2000-11-24 2002-05-28 Daicel Chem Ind Ltd 内分泌撹乱物質結合領域を細胞の表層に有する微生物およびその応用方法
WO2002095405A1 (en) 2001-05-21 2002-11-28 The Regents Of The University Of California Membrane-resident steroid receptors and methods of use thereof
EP1912069A3 (en) * 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
US20060281703A1 (en) * 2005-05-19 2006-12-14 Schering Aktiengesellschaft Treatment of disease using an improved regulated expression system
WO2006127972A2 (en) * 2005-05-26 2006-11-30 Dana-Farber Cancer Institute, Inc. Modulation of muc1-dependent anti-estrogen resistance
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
ES2758227T3 (es) 2013-02-15 2020-05-04 Univ California Receptor de antígeno quimérico y métodos de uso del mismo
EP2968502B1 (en) * 2013-03-14 2020-08-26 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
WO2015017214A1 (en) * 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
CN106132423B (zh) * 2014-02-14 2020-07-31 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
EP3811970A1 (en) * 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
CN106535925A (zh) * 2014-05-23 2017-03-22 佛罗里达大学研究基金会有限公司 基于car的免疫治疗
US10538568B2 (en) * 2014-11-04 2020-01-21 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor
JP6784687B2 (ja) * 2015-02-24 2020-11-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結合誘発型転写スイッチ及びその使用方法
JP2018511602A (ja) * 2015-03-30 2018-04-26 イントレクソン コーポレイション リガンド誘導性ポリペプチドカプラー系
US10988542B2 (en) * 2015-08-24 2021-04-27 Cellectis Chimeric antigen receptors with integrated controllable functions
KR20180096788A (ko) * 2016-01-08 2018-08-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 조건적 활성 이종이량체 폴리펩티드 및 이의 사용 방법

Also Published As

Publication number Publication date
KR20190133734A (ko) 2019-12-03
AU2023200894B2 (en) 2024-07-11
TW201840590A (zh) 2018-11-16
US20180319890A1 (en) 2018-11-08
EP3601330A1 (en) 2020-02-05
US11111310B2 (en) 2021-09-07
JP2024054208A (ja) 2024-04-16
JP2022058725A (ja) 2022-04-12
JOP20180027A1 (ar) 2019-01-30
US11993660B2 (en) 2024-05-28
AU2018244592B2 (en) 2021-03-11
KR20230004870A (ko) 2023-01-06
CN110678480A (zh) 2020-01-10
SG10201912408WA (en) 2020-02-27
SG11201908618SA (en) 2019-10-30
KR20240019863A (ko) 2024-02-14
BR102018006205A2 (pt) 2021-03-23
IL269433A (en) 2019-11-28
WO2018183551A1 (en) 2018-10-04
TWI811212B (zh) 2023-08-11
JP7433348B2 (ja) 2024-02-19
CA3058262A1 (en) 2018-10-04
US20210395386A1 (en) 2021-12-23
TW202409071A (zh) 2024-03-01
JP2020512009A (ja) 2020-04-23
KR102475696B1 (ko) 2022-12-09
AU2018244592C1 (en) 2021-07-08
AU2018244592A1 (en) 2019-10-03
KR20220002751A (ko) 2022-01-06
KR102659440B1 (ko) 2024-04-24
AU2021203626A1 (en) 2021-07-01
AU2023200894A1 (en) 2023-03-23
AU2021203626B2 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
UY37644A (es) Polipéptidos quiméricos y métodos para alterar su localización en la membrana
BR112015022119A2 (pt) Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
ES2545895T3 (es) Proteína de fusión anticancerígena
CL2018000238A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CL2016001134A1 (es) Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.
MY178233A (en) Tagged chimeric effector molecules and receptors thereof
MX2020011788A (es) Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
CL2021001794A1 (es) Péptido, ácido nucleico, célula, composición farmacéutica, linfocito t activado, agente de unión aislado, y tcr, para su uso en inmunoterapia contra el cáncer; y métodos para producirlos (divisional de la solicitud no. 201600227)
BR112012031329A2 (pt) proteínas de fusão diméricas vstm3 e composições e métodos relacionados
CL2016000232A1 (es) Estabilización de polipéptidos que contienen fragmentos cristalizables
MX2016004564A (es) Cultivo celular metabolicamente optimizado.
AR070134A1 (es) Agonistas de plexind1 que comprende un fragmento de semaforina 3e(sema3e) y su uso
UY35456A (es) Moléculas de unión para bcma y cd3
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
BR112016002622A2 (pt) meio e processo de cultura celular, polipeptídeo, uso de selênio ou de um sal do mesmo e uso de zinco ou um sal do mesmo
CL2012003077A1 (es) Polipeptido que comprende el decimo dominio de fibronectina tipo iii (10fn3), en donde el dominio 10fn3 se une al dominio 1 o 2 de seroalbumina humana, y donde la vida media del suero del polipéptido en presencia de seroalbumina es al menos 5 veces mayor que en su ausencia; acido nucleico que lo codifica; vector que lo comprende; celula hospedera que lo expresa; composición que lo comprende; y su uso para tratar la diabetes.
AR088941A1 (es) Anticuerpos anti-fgfr2 y sus usos
BR112012011740A2 (pt) polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii
AR108295A1 (es) Composiciones y métodos para preparar anticuerpos basados en el uso de un locus mejorador de expresión
BR112019011065A2 (pt) métodos para determinação da dosagem de células t car
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
CL2015002705A1 (es) Anticuerpos anti-cd52.
BR112012011598A2 (pt) polipeptídeos de haemophilus parasuis e métodos de uso
WO2018120843A9 (zh) 一种三功能分子及其应用

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231026